Healthcare (SH:603313)2017-10-18 16:00Financial Performance - Net profit attributable to shareholders rose by 2.17% to CNY 144,980,921.47 for the first nine months of the year[6] - Operating revenue for the first nine months increased by 35.87% to CNY 1,659,016,499.02 compared to the same period last year[6] - The company reported a total profit for the first nine months of 2017 was approximately ¥155.58 million, a decrease of 12.8% from ¥178.50 million in the same period of 2016[26] - The total comprehensive income for the first nine months of 2017 was approximately ¥135.06 million, down from ¥140.50 million in the same period of 2016[26] - The company's total profit for the first nine months of 2017 was approximately ¥155.58 million, a decrease of 12.8% from ¥178.50 million in the same period of 2016[26] Revenue and Costs - Total revenue for the year-to-date period reached ¥1,659,016,499.02, representing a 35.87% increase compared to ¥1,221,018,558.00 in the same period last year, primarily driven by growth in external sales[11] - The company reported a 45.81% increase in total operating costs, amounting to ¥1,513,792,265.38, driven by increased sales volume and costs of major raw materials[11] - Operating costs for the first nine months were CNY 1,513,792,265.38, up 45.7% from CNY 1,038,165,855.57 in the previous year[22] - The operating costs for Q3 2017 were approximately ¥359.89 million, up 55.0% from ¥232.16 million in Q3 2016[25] Cash Flow - Net cash flow from operating activities decreased by 63.00% to CNY 58,975,528.05 year-on-year[6] - Operating cash inflow for the year-to-date period reached ¥1,756,910,856.77, an increase of 30% compared to ¥1,352,015,001.93 in the same period last year[28] - Cash flow from operating activities showed a net outflow of ¥86,732,258.06, contrasting with a net inflow of ¥126,726,348.54 in the same period last year[31] - The company's cash flow from financing activities showed a significant decline of ¥891,185,927.89, resulting in a net cash flow of -¥6,443,644.11, primarily due to dividend distributions[12] Assets and Liabilities - Total assets increased by 10.53% to CNY 2,197,754,360.59 compared to the end of the previous year[6] - The company reported a total liability of CNY 525,042,127.67, compared to CNY 162,787,684.98, marking a substantial increase[21] - Current assets totaled CNY 1,409,952,581.11, up from CNY 1,343,269,096.11, indicating an increase of about 4.9%[20] - The company’s total equity decreased to CNY 1,562,240,777.01 from CNY 1,715,178,827.96, a decline of approximately 8.9%[21] Shareholder Information - The total number of shareholders reached 25,899[10] - The largest shareholder, Ni Zhanggen, holds 61.24% of the shares, with 141,641,980 shares pledged[10] Financial Ratios - The weighted average return on equity decreased by 11.7 percentage points to 9.02%[6] - Basic earnings per share decreased by 24.05% to CNY 0.60[6] - The company's financial expenses increased dramatically by 2,007.55% to ¥29,363,843.80, primarily due to foreign exchange losses from the RMB to USD exchange rate fluctuations[11] Government Support - Government subsidies recognized in the first nine months amounted to CNY 22,377,289.57[7] Investment Activities - The company’s investment activities resulted in a net cash outflow of -¥124,139,674.76, attributed to external investments[12] - Investment cash inflow totaled ¥375,251,053.63, significantly up from ¥3,792,413.56 in the previous year[29]